Elixir Energy Limited

EXR

Elixir Energy Ltd. engages in the exploration of oil and gas. The company is headquartered in Adelaide, South Australia. The company went IPO on 2004-07-19. The firm is primarily focused on coal bed methane (CBM) exploration and development in Mongolia, and tight gas appraisal in Queensland and green hydrogen production in Mongolia. The Company’s segments include Oil And Gas Exploration in Australia, Mongolia, the United States of America (USA); Clean Energy in Mongolia; and Solar Project in Mongolia. The firm has a 100% interest in the Nomgon IX CBM production sharing contract (PSC), located proximate to the Chinese border in Mongolia's South Gobi region. The Nomgon Project is located on the Mongolian Chinese border, around 400 kilometers (km) north of China's main gas transmission grid. The Nomgon Project license area covers approximately 30,000 square kilometers. The company also focuses on the green hydrogen production project, Gobi H2 in the South of Mongolia. Its subsidiaries include Golden Horde Pty Ltd, GOH LLC, GOH Clean Energy LLC, among others.

Nova EYE Medical Limited

EYE

Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia. The Company’s principal activities include the design, development, manufacture, marketing, sale, and distribution of surgical devices for the treatment of glaucoma, a cause of blindness. The firm is also engaged in the commercialization of its ophthalmic laser, 2RT. The Company’s segments include AlphaRET and Glaucoma surgical devices. The firm's AlphaRET segment has 2RT, which is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD). 2RT is a patented nano-pause laser device that rejuvenates retinal structures compromised by AMD. The Glaucoma Surgical Devices segment includes the design, manufacture, marketing and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. The firm's manufacturing facilities are located in Fremont, California, and Dunedin, New Zealand.

EX20

EX20.AX was created on 2016-10-05 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 234.2m in AUM and 180 holdings. EX20.AX aims to track the performance of an index (before fees and expenses) comprising the 180 largest stocks listed on the ASX, after excluding the 20 largest, based on their market capitalisation.

Elixinol Wellness Limited

EXL

Elixinol Wellness Ltd. engages in the sale of nutraceutical and related hemp products. The company is headquartered in Sydney, New South Wales. The company went IPO on 2018-01-08. The firm is engaged in marketing and selling hemp-derived nutraceutical, cosmetic and food products. The Company’s operations are focused on various markets, including the Americas, which is engaged in marketing and selling Elixinol branded hemp and other plant-derived nutraceutical and skincare products based in Colorado, United States of America; Australia, which consists of Hemp Foods Australia, which is a hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials and finished product; United Kingdom, South Africa, Japan, Brazil, Mexico and Malaysia (pending approvals), Elixinol branded products, which are available to consumers via distribution and/or trademark and know-how licensing agreements, and the Rest of World, which distributes Elixinol branded hemp-derived products through distributors. The firm trades its products under two core brands: Elixinol and Hemp Foods Australia.